Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Toripalimab Plus Chemotherapy in Urothelial Carcinoma
NCT04099589Phase 2Unknown
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Oct 2019
- Primary completion
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in muscle-invasive bladder cancer (MIBC), upper tract urothelial carcinoma (UTUC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
toripalimab
03
Conditions
muscle-invasive bladder cancer (MIBC)upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT04099589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04099589.